Beovu
News/ News/ Sales and Marketing
Novartis says trials back Beovu safety in diabetic eye disease
Phil Taylor
Bayer, Beovu, diabetic macular oedema, Eylea, Lucentis, Novartis, ophthalmology, Regeneron
0 Comment
FDA starts review of Roche’s eye disease drug, setting up 2022 verdict
Phil Taylor
age-related macular degeneration, Bayer, Beovu, diabetic macular oedema, diabetic retinopathy, Eylea, faricimab, Novartis, ophthalmology, Regeneron, Roche
0 Comment
Roche eyes October decision by FDA for wet AMD implant
Phil Taylor
age-related macular degeneration, Beovu, Eylea, fda, Lucentis, Novartis, ophthalmology, Regeneron, Roche, wet AMD
0 Comment
UK patient group warns COVID could limit access to Novartis’ new eye drug
Richard Staines
Bayer, Beovu, market access, NICE, Novartis, ophthalmology, Regeneron
0 Comment
Novartis taps smartpatient for app to support wet AMD patients
Phil Taylor
app, Beovu, digital, digital health, Lucentis, Novartis, ophthalmology, smartpatient, wet AMD
0 Comment
Novartis’ Beovu safety woes could cost billions of dollars, says analyst
Richard Staines
Bayer, Beovu, Novartis, ophthalmology, Regeneron, safety, wet AMD
0 Comment
Novartis’ blockbuster hope Beovu clears EMA advisory panel
Phil Taylor
age-related macular degeneration, Bayer, Beovu, Eylea, Lucentis, Novartis
0 Comment